NICE has made six times more lung cancer treatment recomendations over the past ten years than in the previous decade
We have also recommended osimertinib for routine use on the NHS today.
We have also recommended osimertinib for routine use on the NHS today.
Recommendations will help organisations that evaluate new drugs establish whether their use will result in longer-term benefits for patients
For the first time, NICE has recommended an innovative new treatment to help stop babies, children and young people who are undergoing cancer treatment from losing their hearing.
We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type of advanced breast cancer.
An end of year summary from our chief executive, Dr Sam Roberts.
A guide to the severity modifier and how it is leading to more positive recommendations overall from NICE.
We explore the ongoing debate around NICE’s cost-effectiveness thresholds and what the future holds.
Dr Patterson, a GP working on the frontline of primary care, describes why he is encouraged by NICE's approval of tirzepatide (Mounjaro).